Arbutus Biopharma (ABUS) Long-Term Debt Repayments (2018)
Arbutus Biopharma's (ABUS) quarterly Long-Term Debt Repayments came in at $12.0 million in Q1 2018.
Arbutus Biopharma (ABUS) Long-Term Debt Repayments (2018) Analysis & Trends
Arbutus Biopharma has disclosed Long-Term Debt Repayments across 1 years of filings, most recently posting $12.0 million for Q1 2018.
- Long-Term Debt Repayments for Q1 2018 came in at $12.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was $12.0 million (changed N/A YoY), and the FY2018 annual result was $12.0 million, changed N/A from the prior year.
- Long-Term Debt Repayments came in at $12.0 million for Q1 2018 at Arbutus Biopharma.
- In the past five years, Long-Term Debt Repayments ranged from a high of $12.0 million in Q1 2018 to a low of $12.0 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -21,671.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arbutus Biopharma | 882.62 Mn | 882.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 12.00 Mn |
| Mar 31, 2018 | 12.00 Mn |